Dolores Vilas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dolores Vilas has a total of 282 co-authors. Here are the top co-authors by number of shared publications:
- Katrin Beyer
Department of Neuroscience Research Institute Germans Trias i Pujol Badalona Spain
10 shared publications Lourdes Ispierto
Movement Disorders Unit, Neurology Department, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
8 shared publicationsMireia Gea
Movement Disorders Unit, Neurology Department Hospital Universitari Germans Trias i Pujol Badalona Spain
6 shared publications- Lourdes Ispierto
Unit of Neurodegenerative Diseases, Department of Neurology, University Hospital Germans Trias i Pujol Badalona, 08916 Barcelona, Spain
5 shared publications - Lourdes Ispierto
Movement Disorders Unit, Department of Neurology University Hospital Germans Trias i Pujol Badalona Spain
5 shared publications - Pau Pastor
Department of Neuroscience Research Institute Germans Trias i Pujol Badalona Spain
5 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by Springer Nature in npj Parkinson's Disease
Nigrosome-1 neuromelanin and iron coupling in idiopathic and GBA-associated Parkinson disease
- 28 October 2026
- Published by Springer Nature in npj Parkinson's Disease
Open AccessNigrosome-1 neuromelanin and iron coupling in idiopathic and GBA-associated Parkinson disease
- Open Access
- 14 October 2026
- Published by Wiley in Movement Disorders
Severe Parkinson's Disease Linked to SNCA Locus Triplication Is Associated with Expression Changes in Platelets: A Case Report
- 14 October 2026
- Published by Wiley in Movement Disorders
Open AccessSevere Parkinson's Disease Linked to SNCA Locus Triplication Is Associated with Expression Changes in Platelets: A Case Report
- Open Access
- 3 August 2026
- Published by Wiley in Movement Disorders
Real‐World Evaluation of Bilateral Magnetic Resonance–Guided Focused Ultrasound Thalamotomy in Essential Tremor
Background: Magnetic resonance–guided focused ultrasound (MRgFUS) thalamotomy is effective in treating essential tremor (ET) with an adequate safety profile. Objective: The aim of the study was to evaluate the real‐world safety and efficacy of staged bilateral MRgFUS thalamotomy in ET and its impact on patient's quality of life (QoL) and patient‐reported outcomes (PROs). Methods: This prospective cohort study included patients with ET who underwent staged bilateral thalamotomy. The primary endpoint was the change in the total Clinical Rating Scale for Tremor (CRST) score from baseline (prior to the first thalamotomy) to after the second treatment. Secondary endpoints included CRST subscales, QoL scales assessed using QoL in ET questionnaire (QUEST), EuroQol‐5 Dimension‐5‐level questionnaire (EQ‐5D‐5L), and patient‐reported outcomes (PROs). Adverse events (AEs) were documented. Results: Fifty‐five patients were included. The CRST total score improved 66.6% from baseline to 6 months after staged bilateral thalamotomy. QUEST score improved by 35.3 points. After the second treatment, 60% of patients reported having at most a mild tremor and 69.2% considered that their tremor was “much improved” or “very much improved.” Six‐months after staged bilateral thalamotomy, 15 (45,4%) patients had at least one adverse event, sensory disturbances being the most frequent (27.3%), followed by instability (12.1%) and dysarthria (12.1%). All AEs were mild, except in one case in which the patient showed moderate perioral paresthesia. Conclusions: Staged bilateral MRgFUS thalamotomy provides significant improvement in tremor severity, functional outcomes, and QoL among patients with ET, although controlled studies should be conducted to confirm these results. The safety profile is adequate, although AEs are slightly higher than after the unilateral treatment. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 3 August 2026
- Published by Wiley in Movement Disorders
Open AccessReal‐World Evaluation of Bilateral Magnetic Resonance–Guided Focused Ultrasound Thalamotomy in Essential Tremor
Background: Magnetic resonance–guided focused ultrasound (MRgFUS) thalamotomy is effective in treating essential tremor (ET) with an adequate safety profile. Objective: The aim of the study was to evaluate the real‐world safety and efficacy of staged bilateral MRgFUS thalamotomy in ET and its impact on patient's quality of life (QoL) and patient‐reported outcomes (PROs). Methods: This prospective cohort study included patients with ET who underwent staged bilateral thalamotomy. The primary endpoint was the change in the total Clinical Rating Scale for Tremor (CRST) score from baseline (prior to the first thalamotomy) to after the second treatment. Secondary endpoints included CRST subscales, QoL scales assessed using QoL in ET questionnaire (QUEST), EuroQol‐5 Dimension‐5‐level questionnaire (EQ‐5D‐5L), and patient‐reported outcomes (PROs). Adverse events (AEs) were documented. Results: Fifty‐five patients were included. The CRST total score improved 66.6% from baseline to 6 months after staged bilateral thalamotomy. QUEST score improved by 35.3 points. After the second treatment, 60% of patients reported having at most a mild tremor and 69.2% considered that their tremor was “much improved” or “very much improved.” Six‐months after staged bilateral thalamotomy, 15 (45,4%) patients had at least one adverse event, sensory disturbances being the most frequent (27.3%), followed by instability (12.1%) and dysarthria (12.1%). All AEs were mild, except in one case in which the patient showed moderate perioral paresthesia. Conclusions: Staged bilateral MRgFUS thalamotomy provides significant improvement in tremor severity, functional outcomes, and QoL among patients with ET, although controlled studies should be conducted to confirm these results. The safety profile is adequate, although AEs are slightly higher than after the unilateral treatment. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- Open Access
- 16 July 2026
- Published by SAGE Publications in Cephalalgia
- Vol. 46 (7)
Periaqueductal gray matter echogenicity: An irreversible marker of chronic migraine?
Aim: Although periaqueductal grey matter (PAG), assessed by transcranial sonography, has been proposed as a biomarker of migraine chronification, its longitudinal evolution remains unknown. This study aimed to evaluate whether changes in clinical diagnosis—from chronic migraine to episodic migraine (CM–EM) or from episodic migraine to chronic migraine (EM–CM)—were associated with modifications in PAG echogenicity. Methods: In a prospective longitudinal cohort study we reanalysed a cohort of 115 participants (65 patients with migraine and 50 controls) previously assessed in a baseline study. The follow-up was performed three years after the initial evaluation, collecting demographic, clinical (migraine-related), and sonographic variables. Results: Ninety-four of the 115 participants were re-evaluated at the longitudinal follow-up. Patients who converted from episodic to chronic migraine (EM–CM, n = 3) showed a significantly larger PAG area (0.22 [0.16–0.23] cm 2 vs. 0.13 [0.12–0.16] cm 2 ; p = 0.043), a greater reduction in PAG echogenicity (−0.52 [−0.52 to −0.24] vs. −0.03 [−0.21 to 0.17]; p = 0.008), and higher heterogeneity (33.88 [31.85–36.72] vs. 26.67 [23.33–38.9]; p = 0.0344) at baseline compared with patients who remained episodic at the follow-up assessment (n = 18). Among patients with chronic migraine at baseline, no significant differences in PAG area, heterogeneity, or echogenicity intensity were observed between those who remained chronic and those who were classified as episodic migraine at follow-up. Conclusion: Patients with chronic migraine who clinically improved (CM–EM) did not show relevant between-assessment differences in the previously described PAG alterations, suggesting the persistence of these alterations despite clinical improvement. In contrast, the small group of patients who underwent EM–CM transformation exhibited increased PAG heterogeneity and area at the follow-up assessment. Further studies with a larger sample size should be performed to confirm these results.
- 16 July 2026
- Published by SAGE Publications in Cephalalgia
- Vol. 46 (7)
Open AccessPeriaqueductal gray matter echogenicity: An irreversible marker of chronic migraine?
Aim: Although periaqueductal grey matter (PAG), assessed by transcranial sonography, has been proposed as a biomarker of migraine chronification, its longitudinal evolution remains unknown. This study aimed to evaluate whether changes in clinical diagnosis—from chronic migraine to episodic migraine (CM–EM) or from episodic migraine to chronic migraine (EM–CM)—were associated with modifications in PAG echogenicity. Methods: In a prospective longitudinal cohort study we reanalysed a cohort of 115 participants (65 patients with migraine and 50 controls) previously assessed in a baseline study. The follow-up was performed three years after the initial evaluation, collecting demographic, clinical (migraine-related), and sonographic variables. Results: Ninety-four of the 115 participants were re-evaluated at the longitudinal follow-up. Patients who converted from episodic to chronic migraine (EM–CM, n = 3) showed a significantly larger PAG area (0.22 [0.16–0.23] cm 2 vs. 0.13 [0.12–0.16] cm 2 ; p = 0.043), a greater reduction in PAG echogenicity (−0.52 [−0.52 to −0.24] vs. −0.03 [−0.21 to 0.17]; p = 0.008), and higher heterogeneity (33.88 [31.85–36.72] vs. 26.67 [23.33–38.9]; p = 0.0344) at baseline compared with patients who remained episodic at the follow-up assessment (n = 18). Among patients with chronic migraine at baseline, no significant differences in PAG area, heterogeneity, or echogenicity intensity were observed between those who remained chronic and those who were classified as episodic migraine at follow-up. Conclusion: Patients with chronic migraine who clinically improved (CM–EM) did not show relevant between-assessment differences in the previously described PAG alterations, suggesting the persistence of these alterations despite clinical improvement. In contrast, the small group of patients who underwent EM–CM transformation exhibited increased PAG heterogeneity and area at the follow-up assessment. Further studies with a larger sample size should be performed to confirm these results.
- Open Access
- 14 April 2026
- Published by Wolters Kluwer Health in Neurosurgery
Impact of Unilateral Magnetic Resonance-Guided Focused Ultrasound Thalamotomy in Quality of Life, Nonmotor Symptoms, and Patient-Reported Outcomes in Essential Tremor
BACKGROUND AND OBJECTIVES: Refractory tremor affects quality of life in patients with essential tremor (ET), often accompanied by nonmotor symptoms (NMS) that further impair daily functioning and well-being. This study aimed to evaluate the effects of magnetic resonance-guided focused ultrasound (MRgFUS) unilateral thalamotomy on quality of life and NMS in patients with refractory ET. METHODS: We conducted a prospective observational study including patients treated with unilateral MRgFUS thalamotomy between February 2022 and March 2025. Evaluations were performed at baseline, Day 7, and 3, 6, and 12 months post-treatment. Tremor severity was assessed using the Clinical Rating Scale for Tremor. Quality of life was measured using the Quality of Life in Essential Tremor Questionnaire and the EuroQol-5-Dimension-5-Level Questionnaire. Depression and anxiety were evaluated via the Geriatric Depression Scale (15-item) and Geriatric Anxiety Inventory. Patient perception was assessed using the Patient Global Impression of Severity and Improvement scales. RESULTS: A total of 187 patients were included; 116 (62.03%) completed 12-month follow-up. Treated side-Clinical Rating Scale for Tremor scores decreased from 17.96 ± 4.55 to 3.77 ± 4.38 at 12 months ( P < .001). Quality of life scores (Quality of Life in ET Questionnaire, EuroQol-5-Dimension-5-Level questionnaire) improved significantly at all follow-up ( P < .05). Geriatric Depression Scale (15-item) and Geriatric Anxiety Inventory scores were significantly reduced at 6 and 12 months ( P < .01). At 12 months, 89.7% of patients described improvement, and 45.22% of patients reported mild tremor at most. CONCLUSION: Unilateral MRgFUS thalamotomy leads to significant, sustained improvements in quality of life and NMS in patients with refractory ET with most patients reporting a marked clinical benefit at 1 year.
- 14 April 2026
- Published by Wolters Kluwer Health in Neurosurgery
Open AccessImpact of Unilateral Magnetic Resonance-Guided Focused Ultrasound Thalamotomy in Quality of Life, Nonmotor Symptoms, and Patient-Reported Outcomes in Essential Tremor
BACKGROUND AND OBJECTIVES: Refractory tremor affects quality of life in patients with essential tremor (ET), often accompanied by nonmotor symptoms (NMS) that further impair daily functioning and well-being. This study aimed to evaluate the effects of magnetic resonance-guided focused ultrasound (MRgFUS) unilateral thalamotomy on quality of life and NMS in patients with refractory ET. METHODS: We conducted a prospective observational study including patients treated with unilateral MRgFUS thalamotomy between February 2022 and March 2025. Evaluations were performed at baseline, Day 7, and 3, 6, and 12 months post-treatment. Tremor severity was assessed using the Clinical Rating Scale for Tremor. Quality of life was measured using the Quality of Life in Essential Tremor Questionnaire and the EuroQol-5-Dimension-5-Level Questionnaire. Depression and anxiety were evaluated via the Geriatric Depression Scale (15-item) and Geriatric Anxiety Inventory. Patient perception was assessed using the Patient Global Impression of Severity and Improvement scales. RESULTS: A total of 187 patients were included; 116 (62.03%) completed 12-month follow-up. Treated side-Clinical Rating Scale for Tremor scores decreased from 17.96 ± 4.55 to 3.77 ± 4.38 at 12 months ( P < .001). Quality of life scores (Quality of Life in ET Questionnaire, EuroQol-5-Dimension-5-Level questionnaire) improved significantly at all follow-up ( P < .05). Geriatric Depression Scale (15-item) and Geriatric Anxiety Inventory scores were significantly reduced at 6 and 12 months ( P < .01). At 12 months, 89.7% of patients described improvement, and 45.22% of patients reported mild tremor at most. CONCLUSION: Unilateral MRgFUS thalamotomy leads to significant, sustained improvements in quality of life and NMS in patients with refractory ET with most patients reporting a marked clinical benefit at 1 year.
- Open Access
- 12 March 2026
- Published by Wiley in Movement Disorders
- Vol. 41 (7) , 1893-1898
Differential Progression of Neuroinflammation in Patients with Isolated Rapid‐Eye‐Movement Sleep Behavior Disorder
Background: Neuroinflammation, measured using [ 11 C]( R )‐PK11195 positron emission tomography (PET), has been reported in isolated rapid‐eye‐movement sleep behavior disorder (iRBD), but its temporal progression is unknown. Objective: The aim was to assess longitudinal progression of neuroinflammation in iRBD patients and its relationship with phenoconversion into Parkinson's disease (PD) or dementia with Lewy bodies (DLB). Methods: Sixteen iRBD patients received longitudinal [ 11 C] (R) ‐PK11195 PET scans over 3 years and were followed up clinically for 8 years to record phenoconversion into PD and DLB. Results: We found significant progression of neuroinflammation in the putamen among other regions, with a trend to cortical increase over 3 years. During the clinical follow‐up, 7 patients converted, and subgroup analyses suggested that the converters differed in progression patterns, with PD converters exhibiting increases and DLB exhibiting decreases in inflammation. Conclusion: This exploratory study suggests that progression of neuroinflammation in iRBD patients depends on their clinical trajectories, and this could be impactful in immune‐modifying treatments. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 12 March 2026
- Published by Wiley in Movement Disorders
- Vol. 41 (7) , 1893-1898
Open AccessDifferential Progression of Neuroinflammation in Patients with Isolated Rapid‐Eye‐Movement Sleep Behavior Disorder
Background: Neuroinflammation, measured using [ 11 C]( R )‐PK11195 positron emission tomography (PET), has been reported in isolated rapid‐eye‐movement sleep behavior disorder (iRBD), but its temporal progression is unknown. Objective: The aim was to assess longitudinal progression of neuroinflammation in iRBD patients and its relationship with phenoconversion into Parkinson's disease (PD) or dementia with Lewy bodies (DLB). Methods: Sixteen iRBD patients received longitudinal [ 11 C] (R) ‐PK11195 PET scans over 3 years and were followed up clinically for 8 years to record phenoconversion into PD and DLB. Results: We found significant progression of neuroinflammation in the putamen among other regions, with a trend to cortical increase over 3 years. During the clinical follow‐up, 7 patients converted, and subgroup analyses suggested that the converters differed in progression patterns, with PD converters exhibiting increases and DLB exhibiting decreases in inflammation. Conclusion: This exploratory study suggests that progression of neuroinflammation in iRBD patients depends on their clinical trajectories, and this could be impactful in immune‐modifying treatments. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- Open Access
- 16 December 2025
- Published by Wiley in Brain Pathology
- Vol. 36 (3) , e70059
14‐3‐3σ up‐regulation in the temporal cortex associates with tau pathology and reactive astroglia in Lewy body disorders
The 14‐3‐3 protein family plays a crucial role in cellular signaling and neuronal survival. Although 14‐3‐3 isoforms have been involved in the etiology of some neurodegenerative disorders, their role remains poorly understood in alpha‐synucleinopathies. In this study, we wanted to characterize 14‐3‐3 gene expression patterns in the brain and periphery of patients with Lewy body pathology (LBP). We analyzed messenger RNA (mRNA) expression of all seven 14‐3‐3 isotypes in the temporal cortex and caudate nucleus of brains with pure and common LBP, as well as in cerebrospinal fluid, peripheral blood, and platelets. Stratifin (SFN) protein expression was assessed by immunohistochemistry and enzyme‐linked immunosorbent assay. Effects of SFN overexpression on astrocyte activation were investigated in vitro. In the temporal cortex of LBP patients, six out of seven 14‐3‐3 genes were significantly downregulated, while SFN was markedly up‐regulated. SFN protein localized to neurofibrillary tangles in the parahippocampal region and reactive astrocytes in white matter. In vitro, SFN treatment induced biphasic changes in astrocytic glial fibrillary acidic protein expression, suggesting a role in glial activation. Peripheral analysis revealed no significant 14‐3‐3 mRNA changes in blood, but platelet expression patterns inversely correlated with brain tissue; six isoforms were up‐regulated, and SFN was strongly downregulated in dementia with Lewy bodies (DLB) platelets. Our findings revealed an important shift in 14‐3‐3 isotype expression in the temporal cortex of LBP patients, where SFN up‐regulation reflected its colocalization with tau pathology and astrocytic reactivity. The inverse expression profile in platelets in DLB highlights their potential as accessible biomarkers for molecular changes occurring in the brain.
- 16 December 2025
- Published by Wiley in Brain Pathology
- Vol. 36 (3) , e70059
Open Access14‐3‐3σ up‐regulation in the temporal cortex associates with tau pathology and reactive astroglia in Lewy body disorders
The 14‐3‐3 protein family plays a crucial role in cellular signaling and neuronal survival. Although 14‐3‐3 isoforms have been involved in the etiology of some neurodegenerative disorders, their role remains poorly understood in alpha‐synucleinopathies. In this study, we wanted to characterize 14‐3‐3 gene expression patterns in the brain and periphery of patients with Lewy body pathology (LBP). We analyzed messenger RNA (mRNA) expression of all seven 14‐3‐3 isotypes in the temporal cortex and caudate nucleus of brains with pure and common LBP, as well as in cerebrospinal fluid, peripheral blood, and platelets. Stratifin (SFN) protein expression was assessed by immunohistochemistry and enzyme‐linked immunosorbent assay. Effects of SFN overexpression on astrocyte activation were investigated in vitro. In the temporal cortex of LBP patients, six out of seven 14‐3‐3 genes were significantly downregulated, while SFN was markedly up‐regulated. SFN protein localized to neurofibrillary tangles in the parahippocampal region and reactive astrocytes in white matter. In vitro, SFN treatment induced biphasic changes in astrocytic glial fibrillary acidic protein expression, suggesting a role in glial activation. Peripheral analysis revealed no significant 14‐3‐3 mRNA changes in blood, but platelet expression patterns inversely correlated with brain tissue; six isoforms were up‐regulated, and SFN was strongly downregulated in dementia with Lewy bodies (DLB) platelets. Our findings revealed an important shift in 14‐3‐3 isotype expression in the temporal cortex of LBP patients, where SFN up‐regulation reflected its colocalization with tau pathology and astrocytic reactivity. The inverse expression profile in platelets in DLB highlights their potential as accessible biomarkers for molecular changes occurring in the brain.
- Open Access
- 19 November 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (22) , 11169
Does Platelet Transcriptome Dysregulation Across the Lewy Body Continuum Mirror Neuronal Dysfunction?
Platelets are increasingly recognized as multifunctional cells with roles extending beyond hemostasis to immune regulation, inflammation, and neurodegeneration. Here, we performed RNA-Seq profiling of platelets from patients with idiopathic REM sleep behavior disorder (IRBD), dementia with Lewy bodies (DLB), Parkinson disease (PD), Alzheimer disease (AD), and healthy controls (CTRLs) to explore disease-specific transcriptomic signatures. Across all groups, the RNA class distribution was similar, dominated by mRNAs (78–80%) and long non-coding RNAs (lncRNAs; 15–16%). DLB platelets displayed a reduced proportion of lncRNAs, suggesting an impaired RNA regulation, whereas IRBD concentrated the highest number of disease-specific lncRNAs, half of which were Y-linked, consistent with the male predominance observed in alpha-synucleinopathies. Differential expression analysis (DEA) revealed extensive transcriptomic remodeling in IRBD and DLB, particularly affecting RNA processing, cytoskeletal organization, and platelet activation pathways, while PD and AD showed minimal changes. These findings suggest a progressive impairment of platelet activation and signaling across the DLB continuum, potentially mirroring neuronal dysfunction. The limited transcriptional deregulation in PD may reflect its pronounced biological heterogeneity, consistent with recent multidimensional disease models. Overall, our study highlights platelets as accessible indicators of early and disease-stage-specific molecular alterations in α-synucleinopathies.
- 19 November 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (22) , 11169
Open AccessDoes Platelet Transcriptome Dysregulation Across the Lewy Body Continuum Mirror Neuronal Dysfunction?
Platelets are increasingly recognized as multifunctional cells with roles extending beyond hemostasis to immune regulation, inflammation, and neurodegeneration. Here, we performed RNA-Seq profiling of platelets from patients with idiopathic REM sleep behavior disorder (IRBD), dementia with Lewy bodies (DLB), Parkinson disease (PD), Alzheimer disease (AD), and healthy controls (CTRLs) to explore disease-specific transcriptomic signatures. Across all groups, the RNA class distribution was similar, dominated by mRNAs (78–80%) and long non-coding RNAs (lncRNAs; 15–16%). DLB platelets displayed a reduced proportion of lncRNAs, suggesting an impaired RNA regulation, whereas IRBD concentrated the highest number of disease-specific lncRNAs, half of which were Y-linked, consistent with the male predominance observed in alpha-synucleinopathies. Differential expression analysis (DEA) revealed extensive transcriptomic remodeling in IRBD and DLB, particularly affecting RNA processing, cytoskeletal organization, and platelet activation pathways, while PD and AD showed minimal changes. These findings suggest a progressive impairment of platelet activation and signaling across the DLB continuum, potentially mirroring neuronal dysfunction. The limited transcriptional deregulation in PD may reflect its pronounced biological heterogeneity, consistent with recent multidimensional disease models. Overall, our study highlights platelets as accessible indicators of early and disease-stage-specific molecular alterations in α-synucleinopathies.
- Open Access
- 14 November 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (11) , 1225
Correction: López-Manzanares et al. Real-World Use of COMT Inhibitors in the Management of Patients with Parkinson’s Disease in Spain Who Present Early Motor Fluctuations: Interim Results from the REONPARK Study. Brain Sci. 2025, 15, 532
There was an error in the original publication
- 14 November 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (11) , 1225
Open AccessCorrection: López-Manzanares et al. Real-World Use of COMT Inhibitors in the Management of Patients with Parkinson’s Disease in Spain Who Present Early Motor Fluctuations: Interim Results from the REONPARK Study. Brain Sci. 2025, 15, 532
There was an error in the original publication